Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization

Robert W. Yeh, Brendan M. Everett, Shi Yin Foo, David J. Dorer, Michael Laposata, Elizabeth M. Van Cott, Ik Kyung Jang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A substantial proportion of patients who undergo cardiac catheterization develop antibodies directed against the heparin/platelet factor 4 (PF4) complex after the procedure, which have been implicated in the pathogenesis of heparin-induced thrombocytopenia. This study attempted to identify factors that predicted the development of these antibodies in a prospective cohort study. Antiheparin/PF4 antibody titers were measured at baseline and again 5 ± 2 days after cardiac catheterization by enzyme-linked immunosorbent assay. A total of 311 patients who underwent cardiac catheterization were included in the analysis. Of these, 25 (8.0%) developed positive antibody levels after catheterization. Patients who had positive antibody test results after catheterization had significantly greater baseline antiheparin/PF4 antibody titers compared with those whose titers remained low (optical density 0.227 vs 0.158, p <0.001). In a logistic regression model, greater baseline antibody titers, a history of heparin exposure, and a lower platelet count at enrollment were the strongest predictors of conversion to positive antiheparin/PF4 antibody titers after cardiac catheterization. It is possible to identify patients at high risk for developing elevated titers of antiheparin/PF4 antibodies on the basis of their baseline clinical characteristics.

Original languageEnglish (US)
Pages (from-to)419-421
Number of pages3
JournalAmerican Journal of Cardiology
Volume98
Issue number3
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Platelet Factor 4
Cardiac Catheterization
Heparin
Antibodies
Catheterization
Logistic Models
Platelet Count
Thrombocytopenia
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Prospective Studies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization. / Yeh, Robert W.; Everett, Brendan M.; Foo, Shi Yin; Dorer, David J.; Laposata, Michael; Van Cott, Elizabeth M.; Jang, Ik Kyung.

In: American Journal of Cardiology, Vol. 98, No. 3, 01.08.2006, p. 419-421.

Research output: Contribution to journalArticle

Yeh, Robert W. ; Everett, Brendan M. ; Foo, Shi Yin ; Dorer, David J. ; Laposata, Michael ; Van Cott, Elizabeth M. ; Jang, Ik Kyung. / Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization. In: American Journal of Cardiology. 2006 ; Vol. 98, No. 3. pp. 419-421.
@article{cfa464b1da8043909345742ae7465ea4,
title = "Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization",
abstract = "A substantial proportion of patients who undergo cardiac catheterization develop antibodies directed against the heparin/platelet factor 4 (PF4) complex after the procedure, which have been implicated in the pathogenesis of heparin-induced thrombocytopenia. This study attempted to identify factors that predicted the development of these antibodies in a prospective cohort study. Antiheparin/PF4 antibody titers were measured at baseline and again 5 ± 2 days after cardiac catheterization by enzyme-linked immunosorbent assay. A total of 311 patients who underwent cardiac catheterization were included in the analysis. Of these, 25 (8.0{\%}) developed positive antibody levels after catheterization. Patients who had positive antibody test results after catheterization had significantly greater baseline antiheparin/PF4 antibody titers compared with those whose titers remained low (optical density 0.227 vs 0.158, p <0.001). In a logistic regression model, greater baseline antibody titers, a history of heparin exposure, and a lower platelet count at enrollment were the strongest predictors of conversion to positive antiheparin/PF4 antibody titers after cardiac catheterization. It is possible to identify patients at high risk for developing elevated titers of antiheparin/PF4 antibodies on the basis of their baseline clinical characteristics.",
author = "Yeh, {Robert W.} and Everett, {Brendan M.} and Foo, {Shi Yin} and Dorer, {David J.} and Michael Laposata and {Van Cott}, {Elizabeth M.} and Jang, {Ik Kyung}",
year = "2006",
month = "8",
day = "1",
doi = "10.1016/j.amjcard.2006.02.048",
language = "English (US)",
volume = "98",
pages = "419--421",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Predictors for the Development of Elevated Anti-Heparin/Platelet Factor 4 Antibody Titers in Patients Undergoing Cardiac Catheterization

AU - Yeh, Robert W.

AU - Everett, Brendan M.

AU - Foo, Shi Yin

AU - Dorer, David J.

AU - Laposata, Michael

AU - Van Cott, Elizabeth M.

AU - Jang, Ik Kyung

PY - 2006/8/1

Y1 - 2006/8/1

N2 - A substantial proportion of patients who undergo cardiac catheterization develop antibodies directed against the heparin/platelet factor 4 (PF4) complex after the procedure, which have been implicated in the pathogenesis of heparin-induced thrombocytopenia. This study attempted to identify factors that predicted the development of these antibodies in a prospective cohort study. Antiheparin/PF4 antibody titers were measured at baseline and again 5 ± 2 days after cardiac catheterization by enzyme-linked immunosorbent assay. A total of 311 patients who underwent cardiac catheterization were included in the analysis. Of these, 25 (8.0%) developed positive antibody levels after catheterization. Patients who had positive antibody test results after catheterization had significantly greater baseline antiheparin/PF4 antibody titers compared with those whose titers remained low (optical density 0.227 vs 0.158, p <0.001). In a logistic regression model, greater baseline antibody titers, a history of heparin exposure, and a lower platelet count at enrollment were the strongest predictors of conversion to positive antiheparin/PF4 antibody titers after cardiac catheterization. It is possible to identify patients at high risk for developing elevated titers of antiheparin/PF4 antibodies on the basis of their baseline clinical characteristics.

AB - A substantial proportion of patients who undergo cardiac catheterization develop antibodies directed against the heparin/platelet factor 4 (PF4) complex after the procedure, which have been implicated in the pathogenesis of heparin-induced thrombocytopenia. This study attempted to identify factors that predicted the development of these antibodies in a prospective cohort study. Antiheparin/PF4 antibody titers were measured at baseline and again 5 ± 2 days after cardiac catheterization by enzyme-linked immunosorbent assay. A total of 311 patients who underwent cardiac catheterization were included in the analysis. Of these, 25 (8.0%) developed positive antibody levels after catheterization. Patients who had positive antibody test results after catheterization had significantly greater baseline antiheparin/PF4 antibody titers compared with those whose titers remained low (optical density 0.227 vs 0.158, p <0.001). In a logistic regression model, greater baseline antibody titers, a history of heparin exposure, and a lower platelet count at enrollment were the strongest predictors of conversion to positive antiheparin/PF4 antibody titers after cardiac catheterization. It is possible to identify patients at high risk for developing elevated titers of antiheparin/PF4 antibodies on the basis of their baseline clinical characteristics.

UR - http://www.scopus.com/inward/record.url?scp=33745932744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745932744&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.02.048

DO - 10.1016/j.amjcard.2006.02.048

M3 - Article

C2 - 16860036

AN - SCOPUS:33745932744

VL - 98

SP - 419

EP - 421

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -